Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and Akt suppression

@inproceedings{Shao2015LiraglutideRL,
  title={Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and Akt suppression},
  author={Yimin Shao and Geheng Yuan and Junqing Zhang and Xiaohui Guo},
  booktitle={Drug design, development and therapy},
  year={2015}
}
Liraglutide, a glucagon-like peptide-1 analog, has been proved to reduce body weight and visceral adipose tissue (VAT) in human studies. In this study, we aimed at examining lipogenetic signal changes in VAT after weight-loss with liraglutide in db/db mice. The mice were divided into two groups: liraglutide-treated group (n=14, 8-week-old, fasting glucose. >10 mmol/L, liraglutide 300 μg/kg twice a day for 4 weeks) and control group (n=14, saline). We found body weight gain and food intake were… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Hypothalamic AMPK and energy balance

  • European journal of clinical investigation
  • 2018

The ratio of dihomo-γ-linolenic acid to deoxycholic acid species is a potential biomarker for the metabolic abnormalities in obesity.

  • FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2017

References

Publications referenced by this paper.
SHOWING 1-10 OF 44 REFERENCES

Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion

C Herrmann, R Göke, +3 authors B. Göke
  • 2015

Similar Papers

Loading similar papers…